Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! Get more Watchlists, Portfolios, Custom Views and Chart Templates with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Nanoviricides Inc (NNVC)

Nanoviricides Inc (NNVC)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE Arca]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE Arca]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 21,595
  • Shares Outstanding, K 21,595
  • Annual Sales, $ 0 K
  • Annual Income, $ -9,470 K
  • EBIT $ -8 M
  • EBITDA $ -8 M
  • 60-Month Beta 1.32
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 2.01

Options Overview Details

View History
  • Implied Volatility 267.24% (+20.02%)
  • Historical Volatility 65.01%
  • IV Percentile 53%
  • IV Rank 15.96%
  • IV High 1,197.14% on 12/15/25
  • IV Low 90.64% on 01/15/26
  • Expected Move (DTE 21) 0.9690 (92.29%)
  • Put/Call Vol Ratio 0.00
  • Today's Volume 161
  • Volume Avg (30-Day) 114
  • Put/Call OI Ratio 0.02
  • Today's Open Interest 3,556
  • Open Int (30-Day) 4,172
  • Expected Range 0.0810 to 2.0190

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 1 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/26
See More
  • Average Estimate -0.13
  • Number of Estimates 1
  • High Estimate -0.13
  • Low Estimate -0.13
  • Prior Year -0.14
  • Growth Rate Est. (year over year) +7.14%

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.8500 +23.53%
on 02/05/26
1.0800 -2.78%
on 01/28/26
-0.0300 (-2.78%)
since 01/27/26
3-Month
0.8500 +23.53%
on 02/05/26
1.4900 -29.53%
on 12/09/25
-0.2100 (-16.67%)
since 11/26/25
52-Week
0.8500 +23.53%
on 02/05/26
2.2299 -52.91%
on 11/05/25
-0.2900 (-21.64%)
since 02/27/25

Most Recent Stories

More News
MPox Orphan Drug Designation Application Filed for NV-387, Declares NanoViricides

SHELTON, CONNECTICUT / ACCESS Newswire / February 12, 2026 / NanoViricides, Inc., a publicly traded company (NYSE American:NNVC) (the "Company"), and a clinical stage, leading global pioneer in the development...

NNVC : 1.0500 (+5.00%)
Measles Orphan Drug Designation Application Filed for NV-387, Declares NanoViricides

SHELTON, CONNECTICUT / ACCESS Newswire / February 10, 2026 / NanoViricides, Inc., a publicly traded company (NYSE American:NNVC) (the "Company"), and a clinical stage, leading global pioneer in the development...

NNVC : 1.0500 (+5.00%)
NanoViricides President Dr. Diwan Interviewed by Mission Matters' Adam Torres

SHELTON, CONNECTICUT / ACCESS Newswire / February 2, 2026 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), a clinical stage leader developing revolutionary broad-spectrum antiviral drugs that...

NNVC : 1.0500 (+5.00%)
NanoViricides Comments on the Need for Broad-Spectrum Antivirals in Light of the Current Influenza Wave - NV-387 is Effective Against H3N2

SHELTON, CONNECTICUT / ACCESS Newswire / January 13, 2026 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), a clinical stage leader developing revolutionary broad-spectrum antiviral drugs that...

NNVC : 1.0500 (+5.00%)
This Clinical-Stage Biotech Just Raised $6M to Advance a Drug That Could Address Pandemic Preparedness Gaps

NanoViricides (NNVC), a clinical-stage antiviral developer, strengthened its financial position in late 2025 with $6.1M in new funding as it advances its lead drug NV-387 toward Phase II tria

NNVC : 1.0500 (+5.00%)
2 Small-Cap Biotechs That Could Reward Patient Investors

Two small-cap biotech stocks offer high risk but significant upside for patient investors as they advance early-stage diagnostic and antiviral programs

NNVC : 1.0500 (+5.00%)
MYNZ : 0.7538 (+2.31%)
NanoViricides Has Signed a Master Services Agreement with OnlyOrphansCote Regarding Orphan Drug Strategy of NV-387 for Treatment of MPox, Smallpox, and Measles

SHELTON, CONNECTICUT / ACCESS Newswire / December 1, 2025 / NanoViricides, Inc., a publicly traded company (NYSE Amer.:NNVC) (the "Company"), and a clinical stage, leading global pioneer in the development...

NNVC : 1.0500 (+5.00%)
NanoViricides, Inc. Has Filed its Quarterly Report - Subsequent Raise Has Fortified Fiscal Position

SHELTON, CONNECTICUT / ACCESS Newswire / November 17, 2025 / NanoViricides, Inc. (NYSE Amer.:NNVC) (the "Company"), reports that it has filed its Quarterly Report on Form 10-Q for the fiscal quarter ending...

NNVC : 1.0500 (+5.00%)
NanoViricides to Present at the Pharma Partnering Summit 2025 in Boston Today, November 14th - NV-387 is Effective Against H3N2

SHELTON, CONNECTICUT / ACCESS Newswire / November 14, 2025 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), a clinical stage leader developing revolutionary broad-spectrum antiviral drugs that...

NNVC : 1.0500 (+5.00%)
NanoViricides Announces Closing of $6 Million Registered Direct Offering and Concurrent Private Placement Priced at the Market Close

SHELTON, CONNECTICUT / ACCESS Newswire / November 12, 2025 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), today announced the closing of its previously announced securities purchase agreement...

NNVC : 1.0500 (+5.00%)

Business Summary

NanoViricides, Inc. is a development stage company focused on creating special purpose nanomaterials for antiviral therapy. The Company's novel nanoviricide class of drug candidates are designed to specifically attack enveloped virus particles and to dismantle them. It also focuses on the development...

See More

Key Turning Points

3rd Resistance Point 1.1300
2nd Resistance Point 1.0900
1st Resistance Point 1.0700
Last Price 1.0500
1st Support Level 1.0100
2nd Support Level 0.9700
3rd Support Level 0.9500

See More

52-Week High 2.2299
Fibonacci 61.8% 1.7028
Fibonacci 50% 1.5399
Fibonacci 38.2% 1.3771
Last Price 1.0500
52-Week Low 0.8500

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar